DOCSLIB.ORG

Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product List PRODUCT LIST Active Pharma Ingredients API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document A Acotiamide Hydrochloride - 773092-05-0 - Almagate EP 66827-12-1 - Aluminum Hydroxide BP, USP 21645-51-2 - C Cimetidine - 51481-61-9 - D Dexlansoprazole - 138530-94-6 - Dexlansoprazole - 313640-86-7 DMF Sesquihydrate Dexrabeprazole Sodium - 171440-18-9 ODMF, Tech Pack E Ecabet Sodium - 86408-72-2 DMF Esomeprazole - 119141-88-7 - Esomeprazole Magneisum - 217087-10-0 - Dihydrate Esomeprazole Magnesium - 161973-10-0 - Esomeprazole Magnesium USP 217087-09-7 CEP, DMF Trihydrate Esomeprazole Potassium IHS 161796-84-5 DMF Esomeprazole Sodium - 161796-78-7 - Esomeprazole Zinc/ 793668-08-3, - - Base/Strontium 119141-88-7 F Famotidine - 76824-35-6 - E Glycopyrrolate - 596-51-0 - H Hydrotelcite BP 12304-65-3 - I Ilaprazole IHS, IP 172152-36-2 DMF Ilaprazole Sodium - 172152-50-0 ODMF, Tech Pack Itopride - 122898-67-3 - Itopride Hydrochloride IHS 122892-31-3 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 1 API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document L Lafutidine - 118288-08-7 - Lansoprazole - 103577-45-3 - Lansoprazole Sodium - 226904-00-3 - M Magaldrate USP 74978-16-8 - Misoprostol 1% dispersion - 51922-46-2 - in HPMC 1H NMR, CoA, HPLC, Nizatidine - 76963-41-2 N Mass, IR O Omeprazole - 73590-58-6 - Omeprazole Magnesium - 95382-33-5 - Omeprazole Sodium - 95510-70-6 - Oxethazaine - 126-27-2 - Oxyphenonium Bromide - 50-10-2 - P Pantoprazole EP, USP 102625-70-7 - Pantoprazole Magnesium - 471293-63-7 - Pantoprazole Sodium - 138786-67-1 ODMF, Tech Pack Pantoprazole Sodium 164579-32-2, - - Sesquihydrate 154644-14-1 Pirenzepine Dihydrochloride EP 29868-97-1 USFDA Monohydrate Propantheline Bromide - 50-34-0 - R Rabeprazole - 117976-89-3 - Rabeprazole Sodium - 117976-90-6 - Ranitidine - 66357-35-5 - Ranitidine Hydrochloride - 66357-59-3 - 90098-04-7, Rebamipide - - 111911-87-6 Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 2 API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document Roxatidine Acetate - 93793-83-0 - Hydrochloride S Siltenzepine - 98374-54-0 - Sucralfate BP, EP, JP, USP 54182-58-0 - T Tenatoprazole Sodium - 335299-59-7 ODMF, Tech Pack Troxipide - 30751-05-4 - V Vonoprazan Base - 881681-00-1 - Vonoprazan Fumarate - 881681-01-2 - Z Zinc L-Carnosine - 132613-07-1 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 3 API Allergy Management Product Pharmacopoeia CAS No. Technical Document A Acrivastine IHS 87848-99-5 ISO Adrenaline Acid Tartrate USP 51-42-3 - Alimemazine BP, EP 84-96-8 - Alinastine - 154541-72-7 - Asapiprant - 932372-01-5 - B Bamifylline Hydrochloride - 20684-06-4 - Bamirastine - 215529-47-8 - Bepotastine Besylate - 190786-44-8 - Bilastine - 202189-78-4 - Bilastine N-Oxide - 2069238-47-5 - Bromophenaromine BP, EP, USP 980-71-2 - Maleate C Carbinoxamine Maleate - 3505-38-2 USDMF Cetirizine Dihydrochloride BP, USP 83881-52-1 WC Chlorpheniramine Maleate BP, USP 113-92-8 EDMF, USDMF D Desloratadine - 100643-71-8 USMDF Dimetindene Maleate - 3614-69-5 CEP Diphenhydramine - 58-73-1 - Diphenhydramine Citrate USP 88637-37-0 - Diphenhydramine BP, IP, USP 147-24-0 - Hydrochloride Doxylamine Succinate EP, USP 562-10-7 WC E Ebastine BP, EP, USP 90729-43-4 WC Ebastine Fumarate - 97928-20-6 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 4 API Allergy Management Product Pharmacopoeia CAS No. Technical Document Embramine - 3565-72-8 - Embramine Hydrochloride - 13977-28-1 - Episnastine Hydrochloride - 108929-04-0 - F Fexofenadine Base - 83799-24-0 - Fexofenadine Hydrochloride - 153439-40-8 - 1244-76-4, Hydroxyzine Hydrochloride - - H 2192-20-3 K Ketotifen Fumarate - 34580-14-8 - L Levocetirizine - 130018-77-8 USDMF Levocetirizine - 130018-87-0 - Dihydrochloride Levocetirizine BP, EP, IP, JP, USP 823178-28-5 - Hydrochloride Loratadine - 79794-75-5 - M Mepyramine Maleate BP, EP 59-33-6 - Mequitazine BP, EP, USP 29216-28-2 GMP Methdilazine Hydrochloride - 1229-35-2 ISO9001 Mizolastine - 108612-45-9 - Oxomemazine - 4784-40-1 - O Hydrochloride P Pheniramine Maleate BP, EP, USP 132-20-7 - Phenylephrine BP, IP, USP 59-42-7 - Phenylephrine Bitartarate BP, USP 14787-58-7 - Phenylephrine - 61-76-7 - Hydrochloride S Suplatast Tosilate - 94055-76-2 - T Thozylamine - 91-85-0 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 5 API Allergy Management Product Pharmacopoeia CAS No. Technical Document Triprolidine Hydrochloride BP, EP, USP 6138-79-0 WC Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 6 API Anaemia Management Product Pharmacopoeia CAS No. Technical Document A Argatroban USP 141396-28-3 - C Calcium Folinate USP 1492-18-8 GMP, WHO-GMP Calcium Levofolinate - 80433-71-2 cGMP D Daprodustat - 960539-70-2 - Deferasirox - 201530-41-8 - F Ferric Carboxy Maltose - 9007-72-1 - Ferric Citrate - 3522-50-7 - Ferric Maltol - 33725-54-1 - Ferrocenecarboxaldehyde - 12093-10-6 cGMP, ISO Ferrous Ascorbate - 24808-52-4 - Ferrous Fumarate BP, IP, USP 141-01-5 - Ferrous Sodium Citrate - 144314-88-5 - Ferrous Succinate - 10030-90-7 - Ferrous Sulphate - 7720-78-7 DC-Grade Ferrous Sulphate Dried - 13463-43-9 - Ferumoxytol - 722492-56-0 - Folic Acid EP, BP, USP 59-30-3 DMF, CEP Iron III Hydroxide Poly - 1310-14-1 - I Maltose Complex Iron Isomaltoside - 1370654-58-2 - Iron Polymaltose Complex - 53858-86-9 - Iron Sorbitol IHS 1338-16-5 - Iron Sucrose - 8047-67-4 DMF, WC Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 7 API Anaemia Management Product Pharmacopoeia CAS No. Technical Document Iron(III) Hydroxide - 20344-49-4 - Iron(III) Hydroxypolymaltose IHS 79173-09-4 - Iron-Dextran - 9004-66-4 - M Methylcobalamin Hydrate - 288315-09-3 - Methylene Blue - 7220-79-3 - Methylthioninium Chloride BP, EP 122965-43-9 - DMF, ISO14001:2004, N Nandrolone Decanoate - 360-70-3 ISO9001:2008, Tech Pack, USFDA DMF, ISO14001:2004, Nandrolone Laurate BP, EP, IP, USP 26490-31-3 ISO9001:2008, Tech Pack, USFDA P Phytonadione (Vitamin K1) - 84-80-0 - R Rivipansel Sodium - 1189037-60-2 ISO Roxadustat - 808118-40-3 - S Sevelamer Carbonate - 845273-93-0 DMF Sevelamer Hydrochloride - 152751-57-0 DMF Sodium Ferric Gluconate - 34089-81-1 - Complex Sucroferric Oxyhydroxide - 12134-57-5 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 8 API Anthelmintics Product Pharmacopoeia CAS No. Technical Document A Alibendol - 26750-81-2 - Avermectin (Abamectin) - 73989-17-0 - B Benznidazole - 22994-85-0 - Buparvaquone - 88426-33-9 - C Clorsulon - 60200-06-8 - Cymiazole - 61676-87-7 - D Diethyl Carbamazine Citrate BP, IP, USP 1642-54-2 - Diloxanide Furoate BP 3736-81-0 - F Febantel BP, EP, IP 58306-30-2 - Fenbendazole BP 43210-67-9 - Fexinidazole 59729-37-2 - I Ivermectin EP 7.0 70161-11-4 - L Levamisole 14769-73-4 - Levamisole Hydrochloride EP 16595-80-5 - Levamisole Phosphate 32093-35-9 - M Mebendazole BP, EP, USP 31431-39-7 - Mepacrine Hydrochloride - 6151-30-0 - Miltefosine - 58066-85-6 - Morantel Tartrate BP, EP, USP 26155-31-7 - Moxidectin - 113507-06-5 - N Niclosamide - 50-65-7 - Nifursemizone - 5579-89-5 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 9 API Anthelmintics Product Pharmacopoeia CAS No.
Load more

Recommended publications
  • The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 2005 The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Pasierb, L. (2005). The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1021 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin A Dissertation presented to the Bayer School of Natural and Environmental Sciences of Duquesne University As partial fulfillment of the requirements for the degree of Doctor of Philosophy By Lisa Pasierb August 26, 2005 Dr. David Seybert, thesis director Dr. David W. Wright, advisor In memory of Anna Pasierb April 24, 1924 – May 31, 2005 ii Acknowledgements First and foremost, I would like to express my sincerest gratitude to my advisor, Dr. David W. Wright. His exuberating energy and conviction attracted me to his research group, while his unwavering faith in me taught me more than he could ever know. Secondly, of course, I would like to extend my appreciation to Glenn Spreitzer and James Ziegler, the other two original members of the Wright group, whom initially tried to exert male dominance, but eventually became very faithful friends and colleagues. Finally, to all the other members of the Wright group over the years, thanks for all of your help, suggestions, and camaraderie.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Domains: 1. Optimizing Medication Use, Using Front- and Back Office Strategies 2
    A SUPPLEMENTARY TABLES Table S1: Domains and themes in the action plan of the Belgian Government (2015-2020) Domains: 1. Optimizing medication use, using front- and back office strategies 2. Continuity of pharmacotherapy in light of transmural care 3. Scientific skills of the hospital pharmacist 4. Transfer of information to and communication with the patient Themes: 2015: anchoring the minimal conditions for the application of clinical pharmacy 2016: development of a structured method for the anamnesis, registration and communication of the medication on admission and discharge 2017: application of clinical pharmacy for specific therapies 2018: application of risk screening for patient groups 2019: application of risk screening for medication groups or pathologies 2020: evaluation of the development of clinical pharmacy in the Belgian hospitals and evaluation of the action plan 2015-2020 Table S2: Anatomical and therapeutic classes of the drugs involved in the discrepancies detected after medication reconciliation n (%) Example(s) of discrepancy Gastro-intestinal system 43 (35.2%) antacids 6 O: antacid PRN antihistaminics 1 O: ranitidine 150 mg 1 pd proton pump inhibitors 5 O: pantoprazole 20 mg 1 pd propulsives 3 O: domperidone PRN; N: alizapride laxatives 9 O: macrogol PRN or 1 pd, bisacodyl PRN or 1 pd antipropulsives 2 O: loperamide 1 pd probiotics 1 O: frequent need for probiotics antidiabetics 1 D: dose repaglinide unknown multivitamins 5 O: multivitamins 1 pd vitamin D 5 O: vitamin D 1 per week vitamin B 2 N: vitamin B complex
    [Show full text]
  • Prevention of Coronary Heart Disease
    PREVENTION OF CORONARY PATIENT WITH CHD HEART DISEASE • Obese male patient with previous angina, cardiac catheterization with placement of two stents and now stable. • Notable clinical characteristics: Thomas F . Wh ayne, J r, MD , PhD, FACC Triglycerides 354 mg/dl. Professor of Medicine (Cardiology) HDL 28 mg/dl in men. Gill Heart Institute BP 140/90 mm/Hg. University of Kentucky Fasting glucose 120 mg/dl. November, 2009 • Specific management? Characteristics of Plaques Prone to HIGH SENSENSITIVITY Rupture From Inflammation and LDL CREACTIVE PROTEIN (hs-CRP) Fibrous cap Media • A MARKER OF INFLAMMATION: CRP AND Lumen Lipid hsCRP ARE SAME PROTEIN Core • MAY BE ANOTHER RISK FACTOR AND PLAY A ROLE IN PLAQUE FORMATION “Vulnerable” plaque • MAY PREDICT HIGH RISK ACUTE CORONARY SYNDROME • MAY INDICATE PATIENTS MOST LIKELY TO Lumen RESPOND TO STATINS T lymphocyte Lipid • STATINS SHOWN TO REDUCE CRP Core Macrophage foam cell (tissue factor) “Activated” Intimal SMC (HLA-DR+) – EZETIMIBE ACCENTUATES THIS EFFECT* “Stable” plaque Normal medial SMC • NEED STATIN DOSE RESPONSE CURVE Libby P. Circulation. 1999; 91:284491:2844--2850.2850. *Sager PT, et al. Am J Cardiol. 2003;92:1414-1418. Resultados Estudio VYTAL sobre PCR: Ezetimiba/Simvastatina vs. Atorvastatina en pts con DM II e Hipercolesterolemia (n=1229) CURRENT CLINICALLY USEFUL MARKERS OF INFLAMMATION Atorvastatina E/Simvas Atorvas E/S 10 mg 20 mg 10/20 40 mg 10/40 0 • LIPOPROTEIN-ASSOCIATED Ezetimiba/ --55 Simvastatina PHOSPHOLIPASE A2*. Atorvastatina ® asales --1010 a Sensibilidad – PLAC TEST. t b --1515 --13.713.7 de Al --13.813.8 • HIGH SENSITIVITY C-REACTIVE --2020 # PCR PROTEIN (hsCRP) .
    [Show full text]
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors Lauren C
    bioRxiv preprint doi: https://doi.org/10.1101/772137; this version posted September 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors Lauren C. Reynolds1, Morgan P. Connolly2,3, Justin B. Siegel1,2,4* 1. Department of Chemistry, University of California Davis, Davis, California, United States of America 2. Genome Center, University of California Davis, Davis, California, United States of America 3. Microbiology Graduate Group, University of California Davis, Davis, California, United States of America 4. Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California, United States of America ABSTRACT: The Type 2 Diabetes Mellitus (T2DM) epidemic undoubtedly creates a need for the development of new phar- maceuticals. With the goal of generating new therapeutics for this disease, computational studies were conducted to design novel dipeptidyl peptidase-4 (DPP-4) inhibitors. Two candidates, generated by chemical intuition-driven design and bioiso- steric replacement, were found to have better docking scores than anagliptin, a currently available diabetes medication. INTRODUCTION debate in recent years for other gliptins as well. A recent Type 2 Diabetes Mellitus (T2DM) is dubbed the meta-analysis seems to suggest a possible increased pan- “epidemic of the 21st century”— affecting millions of pa- creatitis risk for sitagliptin
    [Show full text]
  • Nustendi, INN-Bempedoic Acid, Ezetimibe
    Summary of risk management plan for Nustendi (Bempedoic acid/Ezetimibe) This is a summary of the risk management plan (RMP) for Nustendi. The RMP details important risks of Nustendi, how these risks can be minimized, and how more information will be obtained about Nustendi's risks and uncertainties (missing information). Nustendi's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Nustendi should be used. This summary of the RMP for Nustendi should be read in the context of all this information, including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of Nustendi's RMP. I. The Medicine and What It Is Used For Nustendi is authorized for treatment of primary hypercholesterolemia in adults, as an adjunct to diet (see SmPC for the full indication). It contains bempedoic acid as the active substance and it is given by mouth. Further information about the evaluation of Nustendi’s benefits can be found in Nustendi’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi II. Risks Associated With the Medicine and Activities to Minimize or Further Characterize the Risks Important risks of Nustendi, together with measures to minimize such risks and the proposed studies for learning
    [Show full text]
  • Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial
    Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept trial Sporadic inclusion body myositis (IBM) is the commonest idiopathic inflammatory myopathy (IIM) occurring in patients over the age of 50 years.1-4 The prevalence of IBM differs between different populations and ethnic groups, with estimates between 4.9-70.6 per million population.5-10 IBM is distinguished from the other IIM by early asymmetric finger flexor and knee extensor weakness (leading to loss of hand function and propensity to fall) and resistance to immunosuppressive therapy. Any skeletal muscle can be affected, including oesophageal and pharyngeal muscles. Late-stage disease can be characterized by very significant morbidity including disability and loss of quality of life. Death in IBM is related to malnutrition, cachexia, aspiration, respiratory infection and respiratory failure, as a consequence of dysphagia, severe global weakness and weakness of the respiratory muscles.1-4 In a Dutch cohort, end-of-life care interventions were used by 13% of patients with IBM, highlighting the morbidity experienced by these patients and the need of supportive and palliative care in this disease.2 The aetiopathogenesis of IBM remains uncertain. The varied pathological findings observed have driven a number of theories including viral infection, accumulation of toxic proteins, autoimmune attack, myonuclear degeneration, endoplasmic reticulum stress and impairment of autophagy and proteasomal proteolysis.11-15 Muscle biopsies from patients with IBM typically show several different pathological features broadly described as inflammatory or degenerative. Inflammatory features include endomysial infiltration by mononuclear cells (predominantly CD8+ T- cells), which surround and invade otherwise normal appearing muscle fibres, and overexpression of major histocompatibility complex (MHC) class I, which is not constitutively expressed by skeletal muscle.
    [Show full text]
  • Bempedoic Acid
    Drug Therapy Guidelines Bempedoic Acid (Nexletol [bempedoic acid], Nexlizet [bempedoic acid, ezetimibe]) Applicable Medical Benefit Effective: 5/28/2021 Pharmacy- Formulary 1 x Next Review: 3/23 Pharmacy- Formulary 2 x Date of Origin: 4/23/20 Pharmacy- Formulary 3/Exclusive x Review Dates: 3/20, 3/21 Pharmacy- Formulary 4/AON x I. Medication Description Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) through inhibition of cholesterol synthesis in the liver. Bempedoic acid, an inactive prodrug, and its active metabolite, ESP15228, require coenzyme A (CoA) activation within the liver by very-long-chain acyl CoA synthetase-1 (ACSVL1) to form bempedoic acid-CoA (ETC-1002-CoA) and ESP15228-CoA, respectively. ACSVL1 is primarily expressed in the liver and is absent in adipose tissue and muscles. ACL is an important enzyme that links carbohydrate metabolism to the pathways for cholesterol and fatty synthesis within the liver. Specifically, ACL catalyzes the cleavage of citrate to acetyl-CoA and oxaloacetate within the cholesterol synthesis pathway and is located upstream from HMG-CoA reductase. Both oxaloacetate and acetyl-CoA are important substrates in the synthesis of cholesterol and fatty acids. Thus, inhibition of ACL by bempedoic acid decreases cholesterol and fatty acid synthesis resulting in the upregulation of LDL-C receptors, increased uptake of LDL-C by the liver and reduced blood LDL-C levels. Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols.
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • 200 Adverse Drug Reactions in a Southern Hospital in Taiwan 201
    200 Adverse Drug Reactions in a southern hospital in Taiwan Yuhong Lin1 1Kaohsiung Veterans General Hospital Tainan Branch, Tainan City, Taiwan Objective: The aim of this study was to evaluate the adverse drug reactions (ADRs) reporting in a southern hospital in Taiwan. Methods: It was a retrospective study of ADRs reporting in 2016. We analysed ADRs which contain gender and age, occurring sources, Anatomical Therapeutic Chemical (ATC) classification of suspected drugs, management of ADRs and so on. Results: The study collected eighty-nine ADRs reported. Most of ADRs reported were occurring in outpatient department (87.6%). The average age of ADRs reported was 67.6 years. Majority of all ADRs reported were females (55.1%). According to ATC classification system, the major classification of suspected drugs were Sensory organs (32.6%). Among the adverse reactions, Dermatologic Effects (37.1%) were the major type of ADRs. Also, the major management of ADRs was to stop using the current suspected drug (46.1%). Conclusion: Certainly, ADRs reporting are still a very important information to healthcare professionals. As a result, we put all information of ADRs reported into medical system in our hospital and it will improve the safety of medication use. In case of prescribe the suspected medicines, it can remind doctor to think of information about patient's ADRs reported. No drugs is administered without risk. Therefore, all healthcare professionals should have a responsibility to their patients, who themselves are becoming more aware of problems
    [Show full text]
  • 1 CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on A
    Page 1 of 55 Diabetes CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet Lin Zhu1,2, Thao Luu2, Christopher H. Emfinger1,2, Bryan A Parks5, Jeanne Shi2,7, Elijah Trefts3, Fenghua Zeng4, Zsuzsanna Kuklenyik5, Raymond C. Harris4, David H. Wasserman3, Sergio Fazio6 and John M. Stafford1,2,3,* 1VA Tennessee Valley Healthcare System, 2Division of Diabetes, Endocrinology, & Metabolism, 3Department of Molecular Physiology and Biophysics, 4Devision of Nephrology and Hypertension, Vanderbilt University School of Medicine. 5Division of Laboratory Sciences, Centers for Disease Control and Prevention. 6The Center for Preventive Cardiology at the Knight Cardiovascular Institute, Oregon Health & Science University. 7Trinity College of Art and Science, Duke University. * Address correspondence and request for reprints to: John. M. Stafford, 7445D Medical Research Building IV, Nashville, TN 37232-0475, phone (615) 936-6113, fax (615) 936- 1667 Email: [email protected] Running Title: CETP inhibition and insulin resistance Word Count: 5439 Figures: 7 Tables: 1 1 Diabetes Publish Ahead of Print, published online September 13, 2018 Diabetes Page 2 of 55 Abstract In clinical trials inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels but doesn’t robustly improve cardiovascular outcomes. About 2/3 of trial participants were obese. Lower plasma CETP activity is associated with increased cardiovascular risk in human studies, and protective aspects of CETP have been observed in mice fed a high-fat diet (HFD) with regard to metabolic outcomes. To define if CETP inhibition has different effects depending on the presence of obesity, we performed short- term anacetrapib treatment in chow- and HFD-fed CETP-transgenic mice.
    [Show full text]